MYX Stock Overview
A specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Mayne Pharma Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$4.26 |
| 52 Week High | AU$7.47 |
| 52 Week Low | AU$3.75 |
| Beta | 1.25 |
| 11 Month Change | -8.78% |
| 3 Month Change | -2.74% |
| 1 Year Change | -8.19% |
| 33 Year Change | -27.80% |
| 5 Year Change | -52.13% |
| Change since IPO | -74.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| MYX | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -13.1% | -16.3% | 0.9% |
| 1Y | -8.2% | 35.0% | 17.7% |
Return vs Industry: MYX underperformed the Australian Pharmaceuticals industry which returned 39.8% over the past year.
Return vs Market: MYX underperformed the Australian Market which returned 17.2% over the past year.
Price Volatility
| MYX volatility | |
|---|---|
| MYX Average Weekly Movement | 8.4% |
| Pharmaceuticals Industry Average Movement | 11.9% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 17.2% |
| 10% least volatile stocks in AU Market | 3.3% |
Stable Share Price: MYX has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: MYX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Shawn O’Brien | www.maynepharma.com |
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through three segments: Women’s Health, Dermatology, and International. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women’s health, and infectious disease therapeutic areas.
Mayne Pharma Group Limited Fundamentals Summary
| MYX fundamental statistics | |
|---|---|
| Market cap | AU$339.20m |
| Earnings (TTM) | -AU$168.62m |
| Revenue (TTM) | AU$388.40m |
0.9x
P/S Ratio-2.0x
P/E RatioIs MYX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MYX income statement (TTM) | |
|---|---|
| Revenue | AU$388.40m |
| Cost of Revenue | AU$169.62m |
| Gross Profit | AU$218.78m |
| Other Expenses | AU$387.39m |
| Earnings | -AU$168.62m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.08 |
| Gross Margin | 56.33% |
| Net Profit Margin | -43.41% |
| Debt/Equity Ratio | 7.0% |
How did MYX perform over the long term?
See historical performance and comparison